To include your compound in the COVID-19 Resource Center, submit it here.

Paion's remimazolam meets in Phase III trial for procedural sedation

Paion AG (Xetra:PA8) reported data from a Phase III trial in 431 patients undergoing bronchoscopy showing that procedural sedation with remimazolam (CNS 7056, ONO-2745) met the composite primary endpoint vs. both

Read the full 315 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers